{"id":39194,"date":"2025-11-21T00:21:40","date_gmt":"2025-11-20T17:21:40","guid":{"rendered":"https:\/\/thaipropertynews.com\/feeds\/?p=39194"},"modified":"2025-11-21T00:21:40","modified_gmt":"2025-11-20T17:21:40","slug":"pepromene-bios-pmb-ct01-baffr-car-t-data-selected-for-two-oral-presentations-at-67th-ash-2025-annual-meeting","status":"publish","type":"post","link":"https:\/\/thaipropertynews.com\/feeds\/?p=39194","title":{"rendered":"PeproMene Bio’s PMB-CT01 BAFFR-CAR T Data Selected for Two Oral Presentations at 67th ASH 2025 Annual Meeting"},"content":{"rendered":"\n\n\n
\"\"<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

IRVINE, Calif.<\/span><\/span>, Nov. 20, 2025<\/span><\/span> \/PRNewswire\/ — PeproMene Bio, Inc., a clinical-stage biotechnology company developing novel therapies for relapsed and refractory (r\/r) B-cell malignancies, announced that two abstracts from its ongoing Phase 1 studies of PMB-CT01 (BAFFR-CAR T) have been accepted for oral presentations at the 2025 American Society of Hematology (ASH) Annual Meeting.<\/p>\n

The abstracts showcase the emerging safety and efficacy profile of PMB-CT01 in heavily pretreated r\/r B-cell Acute Lymphoblastic Leukemia (B-ALL) and r\/r B-cell Non-Hodgkin Lymphoma (B-NHL), including patients who failed prior CD19-directed therapy or presented with CD19-negative disease. Interim results from the Phase 1 dose-escalation studies (NCT04690595, NCT05370430) support BAFF-R as a differentiated target designed to overcome CD19 antigen escape while maintaining durable activity and low toxicity.<\/p>\n

r\/r B-NHL<\/u><\/b><\/p>\n

Safety:<\/b>
PMB-CT01 demonstrated an exceptionally favorable tolerability profile. No Grade \u02c31 Cytokine Release Syndrome (CRS) and no Grade \u02c31 Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS)<\/p>\n

Efficacy:<\/b>
All the first 7 patients achieved a Complete Response (CR) at 1\u20133 months post-infusion, including those previously treated with CD19 CAR T therapy and those with CD19-negative disease.<\/p>\n

Durability:<\/b>
Remissions have remained ongoing for up to 32+ months (median 17 months) at data cutoff.<\/p>\n

r\/r B-ALL<\/u><\/b><\/p>\n

Efficacy:<\/b>
Four of six enrolled patients achieved an undetectable Minimal Residual Disease (MRD-) Complete Remission (CR)<\/p>\n

High-Risk Population:<\/b>
Three of the four responders were CD19-negative at enrollment. All three successfully transitioned to allogeneic hematopoietic cell transplant (HCT) with curative intent.<\/p>\n

Safety:<\/b>
No Dose-Limiting Toxicities (DLTs) were observed. Only one patient experienced Grade 2 CRS, with no Grade 3 CRS reported.<\/p>\n

“The consistent and durable activity seen across both B-ALL and B-NHL, particularly in patients who have exhausted CD19 CAR T options or present with CD19-negative disease, strongly supports BAFF-R as a highly effective and safe alternative target,” said Hazel Cheng<\/span>, Ph.D., COO of PeproMene Bio. “These data highlight PMB-CT01’s potential to address critical unmet needs in high-risk relapsed disease.”<\/p>\n

ASH 2025 Oral Presentations<\/b><\/p>\n

Abstract Title: <\/b>BAFFR-CAR T cells demonstrate durable responses and manageable toxicities in r\/r B-cell lymphomas\u2026<\/i>\u00a0
Abstract: <\/b>abs25-7079<\/a>
Date\/Time: <\/b>December 6<\/span>, 2:45 PM<\/span><\/a>
Presenter: <\/b>Elizabeth Budde<\/span>, M.D., Ph.D.\u00a0<\/p>\n

Abstract Title: <\/b>BAFFR-CAR T cells show promising safety and anti-leukemia efficacy in r\/r B-cell ALL patients\u2026<\/i>
Abstract: <\/b>abs25-2035<\/a>
Date\/Time: <\/b>December 8<\/span>, 11:00<\/a>\u00a0AM<\/a>
Presenter: <\/b>Ibrahim\u00a0Aldoss, M.D.<\/p>\n

(Dates\/times are placeholders.)<\/i><\/p>\n

About PMB-CT01<\/b><\/p>\n

PMB-CT01 is a first-in-class BAFF-R\u2013targeted autologous CAR T cell therapy. BAFF-R is expressed almost exclusively on B cells and is essential for B-cell survival, reducing the likelihood of antigen-loss escape. PMB-CT01 is being evaluated in Phase 1 trials for r\/r B-NHL and r\/r B-ALL.<\/p>\n

Forward-Looking Statements<\/b><\/p>\n

This press release contains forward-looking statements subject to risks and uncertainties, including risks related to clinical development, regulatory outcomes, therapeutic potential, and commercialization. PeproMene Bio undertakes no obligation to update forward-looking statements except as required by law.<\/p>\n

Media\/Investor Contact:<\/b>
Hazel Cheng<\/span>, Ph.D.
PeproMene Bio, Inc.
Hazel.Cheng@pepromenebio.com<\/a>\u00a0<\/p>","protected":false},"excerpt":{"rendered":"

<\/p>\n\n\n\n
\"\"<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

IRVINE, Calif.<\/span><\/span>, Nov. 20, 2025<\/span><\/span> \/PRNewswire\/ — PeproMene Bio, Inc., a clinical-stage biotechnology company developing novel therapies for relapsed and refractory (r\/r) B-cell malignancies, announced that two abstracts from its ongoing Phase 1 studies of PMB-CT01 (BAFFR-CAR T) have been accepted for oral presentations at the 2025 American Society of Hematology (ASH) Annual Meeting.<\/p>\n

The abstracts showcase the emerging safety and efficacy profile of PMB-CT01 in heavily pretreated r\/r B-cell Acute Lymphoblastic Leukemia (B-ALL) and r\/r B-cell Non-Hodgkin Lymphoma (B-NHL), including patients who failed prior CD19-directed therapy or presented with CD19-negative disease. Interim results from the Phase 1 dose-escalation studies (NCT04690595, NCT05370430) support BAFF-R as a differentiated target designed to overcome CD19 antigen escape while maintaining durable activity and low toxicity.<\/p>\n

r\/r B-NHL<\/u><\/b><\/p>\n

Safety:<\/b>
PMB-CT01 demonstrated an exceptionally favorable tolerability profile. No Grade \u02c31 Cytokine Release Syndrome (CRS) and no Grade \u02c31 Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS)<\/p>\n

Efficacy:<\/b>
All the first 7 patients achieved a Complete Response (CR) at 1\u20133 months post-infusion, including those previously treated with CD19 CAR T therapy and those with CD19-negative disease.<\/p>\n

Durability:<\/b>
Remissions have remained ongoing for up to 32+ months (median 17 months) at data cutoff.<\/p>\n

r\/r B-ALL<\/u><\/b><\/p>\n

Efficacy:<\/b>
Four of six enrolled patients achieved an undetectable Minimal Residual Disease (MRD-) Complete Remission (CR)<\/p>\n

High-Risk Population:<\/b>
Three of the four responders were CD19-negative at enrollment. All three successfully transitioned to allogeneic hematopoietic cell transplant (HCT) with curative intent.<\/p>\n

Safety:<\/b>
No Dose-Limiting Toxicities (DLTs) were observed. Only one patient experienced Grade 2 CRS, with no Grade 3 CRS reported.<\/p>\n

“The consistent and durable activity seen across both B-ALL and B-NHL, particularly in patients who have exhausted CD19 CAR T options or present with CD19-negative disease, strongly supports BAFF-R as a highly effective and safe alternative target,” said Hazel Cheng<\/span>, Ph.D., COO of PeproMene Bio. “These data highlight PMB-CT01’s potential to address critical unmet needs in high-risk relapsed disease.”<\/p>\n

ASH 2025 Oral Presentations<\/b><\/p>\n

Abstract Title: <\/b>BAFFR-CAR T cells demonstrate durable responses and manageable toxicities in r\/r B-cell lymphomas\u2026<\/i>\u00a0
Abstract: <\/b>abs25-7079<\/a>
Date\/Time: <\/b>December 6<\/span>, 2:45 PM<\/span><\/a>
Presenter: <\/b>Elizabeth Budde<\/span>, M.D., Ph.D.\u00a0<\/p>\n

Abstract Title: <\/b>BAFFR-CAR T cells show promising safety and anti-leukemia efficacy in r\/r B-cell ALL patients\u2026<\/i>
Abstract: <\/b>abs25-2035<\/a>
Date\/Time: <\/b>December 8<\/span>, 11:00<\/a>\u00a0AM<\/a>
Presenter: <\/b>Ibrahim\u00a0Aldoss, M.D.<\/p>\n

(Dates\/times are placeholders.)<\/i><\/p>\n

About PMB-CT01<\/b><\/p>\n

PMB-CT01 is a first-in-class BAFF-R\u2013targeted autologous CAR T cell therapy. BAFF-R is expressed almost exclusively on B cells and is essential for B-cell survival, reducing the likelihood of antigen-loss escape. PMB-CT01 is being evaluated in Phase 1 trials for r\/r B-NHL and r\/r B-ALL.<\/p>\n

Forward-Looking Statements<\/b><\/p>\n

This press release contains forward-looking statements subject to risks and uncertainties, including risks related to clinical development, regulatory outcomes, therapeutic potential, and commercialization. PeproMene Bio undertakes no obligation to update forward-looking statements except as required by law.<\/p>\n

Media\/Investor Contact:<\/b>
Hazel Cheng<\/span>, Ph.D.
PeproMene Bio, Inc.
Hazel.Cheng@pepromenebio.com<\/a>\u00a0<\/p>\n

<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"rop_custom_images_group":[],"rop_custom_messages_group":[],"rop_publish_now":"initial","rop_publish_now_accounts":[],"rop_publish_now_history":[],"rop_publish_now_status":"pending","footnotes":""},"categories":[5,7],"tags":[],"class_list":["post-39194","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-cision-pr-newswire","category-cision-pr-newswire-en"],"_links":{"self":[{"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=\/wp\/v2\/posts\/39194","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=39194"}],"version-history":[{"count":0,"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=\/wp\/v2\/posts\/39194\/revisions"}],"wp:attachment":[{"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=39194"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=39194"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=39194"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}